Republican Sen. Bill Cassidy on Monday night called for federal health officials to postpone this week’s meetings of outside vaccine advisers.

The FDA has expanded the approval of mResvia to include active immunization in high-risk individuals 18 through 59 years of age.

The next time I care for a family that is finally ready to provide the COVID-19 vaccine to their child, I am not sure if they ...

Warren and Duckworth demanded Kennedy make the review public, alongside a similar review the department cited when it cut ...

Vaccine businesses seen as valuable parts of pharma groups but government hostility could deter future developments ...

The epidemiologist and immunologist Michael Mina called Kennedy’s move a “code red” for vaccines in America. Reportedly, none ...

A leading infectious disease expert and one of the nation’s foremost COVID-19 researchers has voiced deep concerns about the ...

NB.1.8.1 is one of the latest variants of COVID-19, a "slightly upgraded version" of the LP.8.1 variant that is prominent ...

President Donald Trump's administration last month canceled a $590-million contract awarded to Moderna in January by outgoing ...

BioNTech said in 2022 that it faced “threats of a groundless patent infringement suit” from a company that was “unable to ...

Among the participants in the present study, 972 developed acute kidney injury, with 411 (42.3%) unvaccinated and 467 (48%) ...

For the 2025-2026 respiratory viral season, Moderna intends to have mResvia available for both FDA-approved patient populations.